Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
Study Identifier:
D6810C00001
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN2220
- Drug: Placebo
Date
Jan 2024 - Jul 2028
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 90 Years
Requirements Information
Sex
Female & Male
Age
18 - 90 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN2220
- Drug: Placebo
Date
Jan 2024 - Jul 2028
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 90 Years years
Requirements Information
Protocol Summary
The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.
Trial Locations
Location
Status
Location
Research Site
Irvine, California, United States, 92614
Status
Recruiting
Location
Research Site
La Jolla, California, United States, 92037
Status
Recruiting
Location
Research Site
Palo Alto, California, United States, 94304
Status
Recruiting
Location
Research Site
San Francisco, California, United States, 94143
Status
Recruiting
Location
Research Site
Aurora, Colorado, United States, 80045
Status
Recruiting
Location
Research Site
Washington, District of Columbia, United States, 20010
Status
Recruiting